{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-25-007708","form_type":"8-K","ticker":"BGLC","cik":"0001737523","company_name":"BioNexus Gene Lab Corp","filed_at":"2025-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.282539+00:00","generated_at":"2026-05-17T02:32:16.824463+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioNexus Gene Lab signs non-binding partnership with BirchBioMed for FS2 topical platform in SE Asia","bullets":["BGLC to lead Birch's $10M financing round; will issue 4.99% of its outstanding common shares to Birch.","BGLC will receive 1.5 million common shares of BirchBioMed in exchange.","Collaboration to commercialize FS2 (kynurenic acid) topical cream in Malaysia and Singapore.","Term sheet non-binding except 60-day exclusivity; no assurance definitive agreement will be reached."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-25-007708","json":"https://secwatch.observer/filing/0001477932-25-007708.json","markdown":"https://secwatch.observer/filing/0001477932-25-007708.md","text":"https://secwatch.observer/filing/0001477932-25-007708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225007708/0001477932-25-007708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225007708/bglc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:32:16.824463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}